Analysts See $-0.61 EPS for Editas Medicine (EDIT); 7 Analysts Are Bullish Coherent, Inc. (COHR) Last Week

October 18, 2017 - By Hazel Jackson

Analysts expect Editas Medicine Inc (NASDAQ:EDIT) to report $-0.61 EPS on November, 6.They anticipate $0.02 EPS change or 3.39% from last quarter’s $-0.59 EPS. After having $-0.65 EPS previously, Editas Medicine Inc’s analysts see -6.15% EPS growth. The stock increased 0.56% or $0.13 during the last trading session, reaching $23.33. About 623,292 shares traded. Editas Medicine Inc (NASDAQ:EDIT) has declined 45.48% since October 18, 2016 and is downtrending. It has underperformed by 62.18% the S&P500.

Among 7 analysts covering Coherent (NASDAQ:COHR), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Coherent had 21 analyst reports since August 3, 2015 according to SRatingsIntel. As per Monday, June 12, the company rating was maintained by Benchmark. The firm has “Buy” rating by Benchmark given on Monday, May 23. The firm has “Buy” rating given on Monday, June 12 by Longbow. The firm earned “Buy” rating on Monday, March 7 by Stifel Nicolaus. The firm has “Buy” rating by Stifel Nicolaus given on Friday, January 29. Needham maintained the stock with “Buy” rating in Wednesday, August 2 report. On Thursday, November 10 the stock rating was maintained by Benchmark with “Buy”. Benchmark maintained the stock with “Buy” rating in Wednesday, August 2 report. The stock of Coherent, Inc. (NASDAQ:COHR) earned “Buy” rating by Needham on Thursday, November 3. Barclays Capital initiated Coherent, Inc. (NASDAQ:COHR) on Monday, August 7 with “Buy” rating. See Coherent, Inc. (NASDAQ:COHR) latest ratings:

07/08/2017 Broker: Barclays Capital Rating: Buy New Target: $285.0000 Initiate
03/08/2017 Broker: Susquehanna Old Rating: Neutral New Rating: Positive Upgrade
02/08/2017 Broker: Needham Rating: Buy New Target: $270.0000 Maintain
02/08/2017 Broker: Benchmark Rating: Buy New Target: $290.0000 Maintain
20/07/2017 Broker: Benchmark Rating: Buy New Target: $295.0000 Maintain
30/06/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $290.0000
28/06/2017 Broker: Longbow Rating: Buy New Target: $325.0000 Maintain
12/06/2017 Broker: Benchmark Rating: Buy New Target: $275.0000 Maintain
12/06/2017 Broker: Longbow Rating: Buy New Target: $325 Maintain

Editas Medicine, Inc. is a genome editing company. The company has market cap of $973.70 million. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It currently has negative earnings. It operates through developing and commercializing genome editing technology segment.

The stock increased 1.96% or $4.99 during the last trading session, reaching $259.88. About 344,205 shares traded. Coherent, Inc. (NASDAQ:COHR) has risen 187.82% since October 18, 2016 and is uptrending. It has outperformed by 171.12% the S&P500.

Coherent, Inc. is a photonics manufacturer. The company has market cap of $6.40 billion. The Firm is engaged in designing, manufacturing, servicing and marketing of lasers and related accessories for a range of scientific, commercial and industrial applications. It has a 38.59 P/E ratio. It operates through two divisions: Specialty Lasers and Systems and Commercial Lasers and Components (CLC).